



Memorandum of Understanding
Between
Center for Disease Analysis Foundation (CDAF)
And
Scientific Research Institute of Virology

This Memorandum of Understanding (MOU) is entered into on the 22nd day of January, 2020 by **Center for Disease Analysis Foundation (CDAF)** of 1120 W. South Boulder Road, Suite 102, Lafayette, CO 80026, USA and the **Scientific Research Institute of Virology (RIV)** of 7 Yangi Shahar Street, Yunusabad Community, Yunusabad District, Tashkent, Uzbekistan, 100133.

This MOU sets forth the terms and understanding between CDAF and RIV as it relates to the Hepatitis Elimination Pilot Program scheduled to be conducted in Tashkent, Uzbekistan starting in December, 2019.

WHEREAS, in connection with the establishment of a business relationship between the parties whereby CDAF's Global Procurement Fund (GPRO) was founded to improve access to quality-assured hepatitis medicines and diagnostics, and whereby RIV's mission includes elimination of hepatitis in Uzbekistan by 2030, the parties wish to set forth their current understanding and certain agreements made to date with respect to such relationship.

The signed parties agree to work together in the spirit of partnership to ensure that there is a visible and responsive leadership of the collaboration, and to demonstrate financial, administrative and managerial commitment to the collaboration.

BACKGROUND

The RIV is a government entity working to eliminate hepatitis in Uzbekistan, and whose mission includes "performing scientific-methodological and coordinating activities in the area of Virology and provision of highly qualified specialized medical care to population on diagnostics, treatment and prevention of viral infectious diseases."

The Center for Disease Analysis Foundation (CDAF) is a non-profit public health research organization specializing in epidemiology and disease modeling. CDAF's mission is to eliminate Hepatitis B and C globally by 2030. We provide countries across the world with verified epidemiological data, disease burden and economic impact modeling, smart intervention strategies, access to affordable diagnostics and treatments, innovative financing models and knowledge-sharing partnerships to eliminate this deadly disease. We accomplish our mission



through two foundation initiatives: The Polaris Observatory and the Global Procurement Fund (GPRO).

In response to a lack of funding from global banks and donor organizations for hepatitis elimination programs, and understanding that many national governments lack the up front capital necessary to fund hepatitis elimination programs, GPRO has developed a catalytic financing model that provides the capital needed to initiate elimination programs. In order to test and validate this new funding model, GPRO has proposed to conduct a pilot program in Tashkent, Uzbekistan. The project consists of three stages, screening of the population, diagnosis and treatment. The stages of screening, diagnostics, rapid tests and all necessary means are free of charge for the population, the test systems and equipment will be transferred to the Research Institute of Virology as humanitarian aid and will be used for non-commercial purposes.

The details of the catalytic funding model and the associated pilot program, including estimated financial benefit to the government of Uzbekistan, sources and amounts of outside capital investment, the roles and responsibilities of the participating organizations and project budget and timelines are described in the attached document titled "*Catalytic Investment Prospectus – Uzbekistan Hepatitis Elimination Pilot (UHEP) Project*".

If the pilot program is successful, CDAF will undertake efforts to raise funds for implementation of a national elimination program.

ROLES & RESPONSIBILITIES

RIV is seeking collaboration with CDAF wherein both parties will work together to conduct a hepatitis elimination pilot program in Tashkent. A summary of the expected pilot project outcomes is as follows:

1. Provide free screening for up to 250,000 people for HBV and HCV
2. Provide free diagnostics for all patients who screen positive for HBV and HCV
3. Provide affordable HBV treatments for an estimated 9,600 people and free HBV treatments for an estimated 2,400 people who cannot afford payment.
4. Provide affordable HCV treatments for an estimated 7,500 people and free HCV treatments for an estimated 1,900 people who cannot afford payment.

In order to achieve the pilot program outcomes described above, CDAF and RIV will work together to coordinate and implement the essential activities of the pilot program.

CDAF will be responsible for the following:

- Overall program design, coordination and execution.
- Initial capital investment to be used for the purchase of diagnostics and medicines
- Through GPRO, CDAF will procure commodities including screening kits, diagnostic reagents and tests and Hepatitis B and Hepatitis C medicines, including shipping, insurance and storage.
- Develop product forecasts and manage supply chain



- Development of a patient registry to collect essential information and manage patient progress through the program from first screening to final treatment.
- Provide all necessary computer equipment and hardware peripherals needed for the operation of the patient registry.
- Sub-contracting for development of all necessary training programs

RIV will be responsible for the following:

- Develop and conduct public awareness campaigns to educate public about the risks and consequences of hepatitis and drive public participation in screening campaigns.
- Provide resources to publicize awareness and education campaigns via TV, radio, website and/or other social media as appropriate.
- Assist in development and delivery of training materials to healthcare workers and doctors as well as provide meeting rooms, projectors and any required payments to healthcare workers for their time.
- Provide in-kind services, labor and equipment for screening and diagnostic testing.
- Provide project management services (CDAF will provide humanitarian assistance) for duration of pilot program.
- Coordinate with the CDAF to identify those patients who cannot afford to pay for the treatment and provide these patients with free treatments at the RIV.
- Efficient customs clearance of humanitarian supplies and delivery to RIV for storage and subsequent distribution to Polyclinics.
- Coordinate the implementation of information technology systems that contain patient specific data on the Ministry of Health servers.

FUNDING

CDAF will provide the following funding:

- The initial up front capital for the pilot program. The amount contributed is described in detail in the attached prospectus.
- Funding for advisory board meetings through the duration of the pilot program.

RIV is not providing any direct funding for the pilot program. RIV will provide in-kind contributions of services as summarized above.

TERM



This MOU is an extension of a previously signed MOU (December 6, 2018). The term of this MOU will begin upon signing and will extend through December 31, 2021 to allow sufficient time to complete the program (18 months, including patient follow-up testing) and to conduct data analysis and final reports. The MOU may be extended upon mutual agreement of RIV and CDAF.



MARKETING and PUBLICITY

CDAF and RIV may promote their collaboration to relevant sectors of the health care community, through regular and other communications, and through their respective websites, social media, and annual reports. Both CDAF and RIV will be bound by the rules for promotion of the other partner; including maintaining the quality of any logo.

CONTACT INFORMATION

Center for Disease Analysis Foundation	Scientific Research Institute of Virology
Homie Razavi Senior Director 1120 W. South Boulder Road, Suite 102 Lafayette, CO 80026 USA +1 720.890.4848 hrazavi@cdafound.org	Erkin Musabaev Director 7 Yangi Shahar Street, Yunusabad Community, Yunusabad District Tashkent, Uzbekistan, 100133 +998 90 186 9184 drmusaev@rambler.com
Homie Razavi Name (print)	Erkin Musabaev Name (print)
Managing Director Title	Director Title
 Signature	 Signature
22 January 2020 Date	22.01.2020 Date